AC Immune (ACIU) EBIT (2015 - 2026)
AC Immune (ACIU) reported EBIT of -$18.9 million for Q1 2026, up 12.35% year-over-year from -$16.8 million in Q1 2025, and down 4.86% on a QoQ basis from -$18.0 million in Q4 2025.
AC Immune (ACIU) has 12 years of EBIT data on file, last reported at -$18.9 million in Q1 2026.
- Quarterly EBIT rose 12.35% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$80.5 million (down 39.83% YoY) and the FY2025 annual result came in at -$83.6 million, down 39.83% from the prior year.
- EBIT eased to -$18.9 million in Q1 2026 per ACIU's latest filing, from -$18.0 million in the prior quarter.
- Across five years, EBIT topped out at $8.4 million in Q3 2024 and bottomed at -$23.4 million in Q2 2025.
- The 5-year median for EBIT is -$19.4 million (2022), against an average of -$17.3 million.
- Peak annual rise in EBIT reached 147.92% in 2024, while the deepest fall reached 432.39% in 2024.
- Tracing ACIU's EBIT over 5 years: stood at -$19.4 million in 2022, then soared by 79.43% to -$4.0 million in 2023, then plunged by 432.39% to -$21.3 million in 2024, then rose by 15.26% to -$18.0 million in 2025, then retreated by 4.86% to -$18.9 million in 2026.
- Per Business Quant, the three latest ACIU EBIT figures stand at -$18.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$20.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | -18.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.88 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -20.21 Mn |
| Jun 30, 2025 | -23.42 Mn |
| Mar 31, 2025 | -21.54 Mn |
| Dec 31, 2024 | -21.25 Mn |
| Sep 30, 2024 | 8.39 Mn |
| Jun 30, 2024 | -23.18 Mn |
| Mar 31, 2024 | -22.99 Mn |
| Dec 31, 2023 | -3.99 Mn |
| Sep 30, 2023 | -17.51 Mn |
| Jun 30, 2023 | -18.96 Mn |
| Mar 31, 2023 | -19.00 Mn |
| Dec 31, 2022 | -19.41 Mn |
| Sep 30, 2022 | -13.94 Mn |
| Jun 30, 2022 | -20.62 Mn |
| Mar 31, 2022 | -20.39 Mn |
| Dec 31, 2021 | -24.71 Mn |
| Sep 30, 2021 | -22.09 Mn |
| Jun 30, 2021 | -20.50 Mn |
| Mar 31, 2021 | -19.08 Mn |
| Dec 31, 2020 | -21.53 Mn |
| Sep 30, 2020 | -20.43 Mn |
| Jun 30, 2020 | -16.28 Mn |
| Mar 31, 2020 | -7.55 Mn |
| Dec 31, 2019 | -19.02 Mn |
| Sep 30, 2019 | 18.25 Mn |
| Jun 30, 2019 | -14.73 Mn |
| Mar 31, 2019 | 60.40 Mn |
| Dec 31, 2018 | -14.56 Mn |
| Sep 30, 2018 | -12.37 Mn |
| Jun 30, 2018 | -11.75 Mn |
| Mar 31, 2018 | -11.94 Mn |
| Dec 31, 2017 | 12.18 Mn |
| Sep 30, 2017 | -17.45 Mn |
| Jun 30, 2017 | -10.86 Mn |
| Mar 31, 2017 | -7.80 Mn |
| Dec 31, 2016 | 13.86 Mn |
| Sep 30, 2016 | -8.28 Mn |
| Mar 31, 2016 | -5.82 Mn |
| Dec 31, 2015 | -6.37 Mn |
| Sep 30, 2015 | 20.06 Mn |